Core Viewpoint - Deutsche Bank has initiated coverage on AtaiBeckley Inc. with a 'Buy' rating and a price target of $12, indicating a potential upside of approximately 320% from current levels [1]. Company Overview - AtaiBeckley is positioned in the emerging field of psychedelic medicine for mental health, recognized as a trailblazer among psychedelic companies that are gaining traction as legitimate drug developers [2]. - The company is focusing on treatment-resistant depression, an area with significant unmet medical needs, through its lead programs BPL-003 and VLS-01 [2]. Product Pipeline - BPL-003 and VLS-01 are expected to leverage the existing Spravato commercial model while potentially displacing both Spravato and first-generation psychedelics due to their rapid-acting and durable effects [3]. - AtaiBeckley's third program, EMP-01, aimed at seasonal affective disorder, is described as a "call option," indicating potential high reward with associated risks [3]. Financial Valuation - Deutsche Bank's risk-adjusted discounted cash flow model suggests that AtaiBeckley shares are materially undervalued, with an upside of approximately 3.5 times compared to a downside of about 70% in the base-case valuation [3]. - Upcoming Phase 2 data for VLS-01 and Phase 2a Part 4 data for BPL-003 are anticipated in the second half of 2026 and fourth quarter of 2026, respectively, which could serve as near-term catalysts for the stock [3].

Core Viewpoint - Noveris Health Sciences Inc. is currently facing a trading halt imposed by the British Columbia Securities Commission due to unusual trading activity and has clarified misinformation regarding its FDA registration status [1][2]. Group 1: Trading Halt - The British Columbia Securities Commission issued an order halting all trading in Noveris Health Sciences Inc.'s securities until April 16, 2026, due to unexplained fluctuations in trading volume and market price [1]. - The company intends to cooperate fully with the BCSC to meet any conditions necessary for the resumption of trading [3]. Group 2: Clarification on Misinformation - Noveris Health Sciences Inc. has not authorized or been involved in the creation or distribution of an article by John Michaels, which inaccurately claimed that the company is FDA-registered [2]. - The company confirms it has no registrations with the FDA and is not pursuing any applications for registration for its products at this time [2]. Group 3: Company Overview - Noveris Health Sciences Inc. is a biotechnology company focused on developing innovative medications and therapies for mental health disorders, including nicotine addiction and PTSD [4]. - The company's strategy combines advanced technology with a robust infrastructure for drug discovery and development, aiming to create breakthrough treatment solutions [4]. - Noveris is also focusing on the next generation of psychedelic medicine, developing innovative compounds with significant therapeutic potential through clinical trials [4].

Core Viewpoint - Noveris Health Sciences Inc. has announced the conversion of debentures totaling $8,188,628 into 47,687,939 common shares, initiated by the debenture holders [1][2]. Group 1: Debenture Conversion Details - The debentures converted at a price of $0.192682432, which is based on the 20-day trailing volume-weighted average trading price of the Company's common shares as of the conversion date [2]. - JJK Holdings Ltd. converted a debenture worth $7,878,792 into 40,890,039 common shares, with the debenture having been transferred to 23 parties prior to conversion [3]. - CEO Joshua Bartch converted his debenture of $1,309,836 into 6,797,900 common shares, increasing his total holdings to 6,827,419 shares, representing 13.95% of the Company's issued shares [4][6]. Group 2: Shareholder Information - Following the conversion, JJK, through its subsidiary, holds 3,848,706 common shares, which is 7.86% of the Company's issued shares [4]. - Prior to the conversion, the Company had 1,235,061 common shares outstanding, and the conversion of the JJK Debenture could have resulted in a significant increase in shares held by JJK [4]. - Mr. Bartch's conversion of his debenture could have resulted in a larger percentage of ownership had the conversion price been different [6]. Group 3: Company Overview - Noveris Health Sciences Inc. is focused on developing innovative medications and therapies for mental health disorders, including nicotine addiction and PTSD [9]. - The Company aims to blend advanced technology with a robust infrastructure for drug discovery and development, aspiring to accelerate the development of breakthrough medications [9]. - Noveris is also concentrating on the next generation of psychedelic medicine, creating innovative compounds with significant therapeutic potential [9].

Summary of COMPASS Pathways Update Webinar Company Overview - **Company**: COMPASS Pathways (NasdaqGS:CMPS) - **Focus**: Development of COMP360, a treatment for treatment-resistant depression (TRD) Key Industry Insights - **Market Need**: Over 4 million adults in the U.S. suffer from TRD annually, with a significant burden compared to major depressive disorder (MDD) [4][34] - **Current Treatments**: Only one approved medication for TRD (Spravato), which requires multiple treatments to achieve similar effects to COMP360 [6][35] - **Economic Burden**: Medication-treated MDD costs nearly $100 billion annually, with TRD patients accounting for almost 50% of these costs due to ineffective treatments [35] Clinical Trial Results - **Trials Conducted**: COMP005 and COMP006, both phase 3 trials for COMP360 - **Primary Endpoint Achievement**: COMP360 met primary endpoints with high statistical significance in three consecutive trials [5][6] - **Efficacy**: - In COMP005, 25% of patients achieved a clinically meaningful reduction in symptoms by week six, sustained through 26 weeks [5][21] - In COMP006, this figure increased to 39% [5][19] - **Rapid Onset**: Patients typically respond within one day of treatment, with durable effects observed [5][6][37] - **Safety Profile**: COMP360 demonstrated a well-tolerated safety profile, with serious adverse events (SAEs) of suicidal ideation below 1% [27][32] Regulatory and Commercial Strategy - **FDA Interaction**: Submitted data to the FDA and requested a meeting to discuss NDA filing strategy, including potential for rolling submission and expedited review [7][42] - **Launch Readiness**: Plans to be launch-ready by the end of the year, with ongoing preparations for commercial rollout [33][39] - **Market Positioning**: COMP360 is positioned to be a leading treatment option for TRD, with a differentiated profile compared to existing therapies [33][38] Additional Insights - **Patient Population**: Trials focused on a highly symptomatic, treatment-resistant population, with a mean MADRS score of 32 [12][13] - **Retreatment Rates**: Approximately 70% of patients in the 25 mg arm of COMP005 opted for retreatment, indicating a strong interest in ongoing treatment [85] - **Commercial Potential**: If approved, COMP360 could significantly change the treatment landscape for TRD, with potential blockbuster revenue given the current market dynamics [38][40] Conclusion - COMPASS Pathways is on track to potentially revolutionize the treatment of TRD with COMP360, addressing a significant unmet need in the mental health space while preparing for a strategic market entry.

As filed with the U.S. Securities and Exchange Commission on October 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the ...

Core Insights - Clearmind Medicine Inc. is participating in a webinar focused on women in psychedelic leadership, highlighting its commitment to advancing psychedelic medicine [1][2] - The CEO, Dr. Adi Zuloff-Shani, will share insights on the company's strategic direction and the broader psychedelic landscape [2][3] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel neuroplastogen-derived therapeutics for under-treated health issues, including alcohol use disorder, cocaine addiction, and obesity [1][4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as needed [5] Event Details - The webinar titled "Women in Psychedelic Leadership: Driving Innovation & Governance" is scheduled for October 29, 2025, at 9:00 AM PT/noon ET, and will be accessible online [1][2][3] - Registration for the event is available through Eventbrite, inviting investors, researchers, and stakeholders to participate [3]

Core Insights - Clearmind Medicine Inc. has appointed Mary-Elizabeth Gifford as Chief of Global Impact to enhance US partnerships and regulatory advocacy in the psychedelic medicine sector [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogens-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of 19 patent families with 31 granted patents and aims to expand this portfolio opportunistically [5] Leadership and Expertise - Mary-Elizabeth Gifford previously served as Chief of Global Impact at Psyence BioMed and has extensive experience in psychedelic policies and regulatory landscapes [2][3] - Gifford has been recognized as a significant figure in the psychedelic industry, being named a "Psychedelic Titan" and described as "the most quietly influential woman working in psychedelics today" [3] Strategic Initiatives - Gifford's role will focus on bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines [1][3] - Clearmind is conducting clinical trials at prestigious institutions such as Yale School of Medicine and Johns Hopkins University, aiming to set industry standards for scientific rigor [3]

Core Insights - Atai Life Sciences is focused on transforming mental health care through next-generation psychedelic therapies, including VLS-01 for treatment-resistant depression and EMP-01 for social anxiety [1][2] - The company has a market capitalization of $1.3 billion and is looking to acquire Beckley Psytech to enhance its capabilities in psychedelic medicine [2] - Recent market activity shows strong investor confidence, with ATAI stock experiencing significant gains and a bullish outlook from analysts [3][7] Company Overview - Atai Life Sciences is a clinical-stage biotech based in Berlin and the Netherlands, specializing in psychedelic compounds and digital therapeutics for mental health disorders [2] - The company has a robust pipeline of therapies aimed at addressing unmet needs in mental health, particularly for conditions like depression and anxiety [5][6] Financial Performance - In Q2 2025, Atai reported revenue of $719,000, a 163% year-over-year increase, while net loss per share improved to $0.14 [10] - R&D expenses decreased to $11.1 million, reflecting cost management efforts, while general and administrative expenses rose to $14.9 million due to strategic initiatives [11] - Cash reserves increased to $95.9 million, bolstered by equity issuances and asset sales, positioning the company well for future growth [12] Market Activity - ATAI shares have surged 411% over the past 52 weeks, with a notable increase of 338% in 2025 and 281% over the last six months [7] - The stock reached an all-time high of $6.75 on October 20, 2025, indicating strong market interest and trading volume [8] Regulatory and Policy Developments - North Carolina is emerging as a leader in psychedelic therapy access, with bipartisan support for policy changes aimed at expanding treatment options [4][15] - A proposed Psychedelic Medicine Task Force and a $5 million research grant program are in the works to study the therapeutic potential of psychedelics [16] Analyst Expectations - Needham initiated coverage on ATAI stock with a "Buy" rating and a price target of $12, citing significant upside potential in its psychedelic pipeline [18] - Analysts project that Atai's lead candidate, BPL-003, could capture 20% of the market, potentially exceeding $2.5 billion in sales by 2035 [19] - The overall analyst sentiment is positive, with eight out of ten analysts recommending a "Strong Buy" rating for ATAI stock [19]

Core Points - Mydecine Innovations Group Inc. announced the results of its annual general and special meeting of shareholders held on October 1, 2025, where all resolutions were approved [1][2] Debt Settlements with Related Parties - Disinterested shareholders approved the settlement of debts totaling USD $1,386,391 owed to two insiders through the issuance of convertible debentures amounting to USD $100,000 [3] - A debt settlement agreement with CEO Josh Bartch was approved to settle CAD $1,309,836 of unpaid management fees, with a convertible debenture issued for the same amount [4] - The company settled CAD $7,878,792 owed to Pioneer Garage Limited through a convertible debenture with the same terms as the Bartch agreement [5] - The Settlement Debentures will not accrue interest prior to an event of default, with an interest rate of 8% per annum upon default [6] Debt Settlement with an Arm's Length Party - A debt settlement agreement was made with an arm's length creditor to settle CAD $243,479 of legal fees through a secured convertible debenture of USD $100,000, bearing 1% monthly interest [9][10] Share Consolidation - Shareholders approved a special resolution allowing the Board to consolidate the company's issued and outstanding common shares on a basis of up to one post-consolidation share for every 50 pre-consolidation shares [13]

Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for unmet mental health needs [5] - It is the first life sciences biotechnology company specializing in psychedelic-based therapeutics to be listed on Nasdaq [5] - The company aims to address unmet mental health needs, particularly in palliative care, through an evidence-based approach [5] Upcoming Events - Psyence BioMed will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8–10, 2025 [1][9] - Dr. Neil Maresky, CEO of Psyence BioMed, will discuss the company's business strategy and pipeline during the conference [2] - A webinar for investors and shareholders is scheduled for September 16, 2025, featuring members of the Scientific Advisory Board [4] Strategic Positioning - The company emphasizes its unique operational footprint in Africa and commitment to clinical excellence as key differentiators in the psychedelic medicine sector [3] - Psyence BioMed aims to engage with global investors to highlight its differentiated approach in the industry [3]